After confirming the knockdown effect of siRNA-PDIA4 by detecting the expression level of Erp72, the in vitro validation of PDIA4’s efficacy in GBM efferocytosis revealed that inhibiting PDIA4 increased PS exposure of GBM cells. This evidence concerns the gene PDIA4 and glioblastoma.